| Rheumatoid Arthritis
Kevzara vs Remicade
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Kevzara vs Remicade with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRemicade has a higher rate of injection site reactions vs Kevzara based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Remicade but not Kevzara, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kevzara
Remicade
At A Glance
SC injection
Every 2 weeks
IL-6 receptor antagonist
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Polymyalgia Rheumatica
- Juvenile polyarthritis
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis 200 mg SC injection once every 2 weeks; may be used as monotherapy or in combination with methotrexate or other conventional DMARDs.
Polymyalgia Rheumatica 200 mg SC injection once every 2 weeks in combination with a tapering course of corticosteroids; may be used as monotherapy following discontinuation of corticosteroids.
Juvenile polyarthritis 200 mg SC injection once every 2 weeks for patients weighing 63 kg or greater; may be used as monotherapy or in combination with conventional DMARDs.
Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.
Contraindications
- Known hypersensitivity to sarilumab or any of the inactive ingredients
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
Adverse Reactions
Most common (>=3%) Neutropenia, increased ALT, injection site erythema, upper respiratory tract infections, urinary tract infections
Serious Serious infections (pneumonia, cellulitis), gastrointestinal perforation, hypersensitivity reactions, neutropenia, thrombocytopenia, elevated liver enzymes, lipid abnormalities
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.
Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.
Pharmacology
IL-6 receptor antagonist; sarilumab is a human recombinant IgG1 monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), inhibiting IL-6-mediated pro-inflammatory signaling involved in T-cell activation, acute phase protein synthesis, and joint inflammation.
TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kevzara
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Remicade
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
UnitedHealthcare
Kevzara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (2/8)
Remicade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kevzara
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Remicade
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Remicade.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KevzaraView full Kevzara profile
RemicadeView full Remicade profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.